Mandate

Vinge advises Internationella Engelska Skolan in connection with listing on Nasdaq Stockholm

September 29, 2016

The prospectus was published on 19 September 2016 and the first day of trading on Nasdaq was 29 September 2016. The offer price was SEK 52 per share, which corresponded to a market value for the total number of shares in the company of MSEK 2 083. The total value of the offering amounted to MSEK 599 provided an overallotment option was exercised in its entirety. No shares or other securities were issued by IES in connection with the offering.

IES is one of the leading independent actors within education in Sweden with approximately 21 400 pupils distributed among 30 schools as of the start of school for the academic year 2016/2017 and with pupils from 50 per cent of the country’s municipalities. IES conducts school operations from grade 1 of the nine-year compulsory school up to and including grade 3 at upper secondary school. The main part of the operations is conducted for students in grades 4 to 9, which is designated internationally as middle school. Within the nine-year compulsory school segment, IES is the leading education provider in terms of the number of pupils and runs 9 of the 10 largest independent schools in Sweden.

Vinge’s team primarily consisted of partner Jesper Schönbeck together with associates Jo-Anna Nordström, Nils Fredrik Dehlin, André Isacson and Ludvig Belke. Partner Louise Brorson Salomonson and associate Helena Håkansson advised on financing issues and associate Henrik Wastersson advised on tax issues. 

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026